Corcept Oncology chief holds 480K stock options
President, Oncology Roberto Wandenkolk Vieira reports direct ownership of common shares and significant stock option awards in CORT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
CORCEPT THERAPEUTICS INC (CORT) reports the initial equity holdings of Roberto Wandenkolk Vieira, who serves as President, Oncology. He directly holds 4,068 shares of Common Stock, including unvested restricted stock awards, and three option grants to purchase up to 480,000 shares of Common Stock at exercise prices of $21.63, $60.58 and $35.70 with expirations in 2034, 2035 and 2036.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Vieira Roberto Wandenkolk
Role
President, Oncology
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy) F2 | -- | -- | -- |
| holding | Stock option (right to buy) F3 | -- | -- | -- |
| holding | Stock option (right to buy) F4 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 480,000 contracts (Direct);
Common Stock — 4,068 shares (Direct)
Footnotes (4)
- F1. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards vested or will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. There were originally 400,000 shares subject to the stock option and an aggregate of 200,000 shares have been previously exercised. The shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
- F3. Exercisable ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.
- F4. Exercisable ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.
Key Figures
Direct Common Stock holding: 4,068 shares
Option underlying shares at $21.63: 200,000 shares
Option underlying shares at $60.58: 140,000 shares
+4 more
7 metrics
Direct Common Stock holding
4,068 shares
Directly held by Roberto Wandenkolk Vieira as of September 1, 2026
Option underlying shares at $21.63
200,000 shares
Remaining shares under option exercisable at $21.63, expiring February 1, 2034
Option underlying shares at $60.58
140,000 shares
Shares under option exercisable at $60.58, expiring February 28, 2035
Option underlying shares at $35.70
140,000 shares
Shares under option exercisable at $35.70, expiring February 27, 2036
Originally granted shares under $21.63 option
400,000 shares
Original size of the option before 200,000 shares were exercised
Previously exercised shares from $21.63 option
200,000 shares
Shares already exercised from the original 400,000-share option grant
Unvested restricted stock awards included in holding
1,408 shares
Sum of unvested awards of 199, 179, 396 and 634 shares included in 4,068-share holding
Key Terms
restricted stock awards, vested or will vest, stock option (right to buy), exercisable ratably in equal installments, +1 more
5 terms
restricted stock awards financial
"Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
vested or will vest financial
"100% of the shares underlying the restricted stock awards vested or will vest on the one-year anniversary"
stock option (right to buy) financial
"There were originally 400,000 shares subject to the stock option and an aggregate of 200,000"
exercisable ratably in equal installments financial
"Exercisable ratably in equal installments on each monthly anniversary of February 28, 2025"
continued service financial
"subject to the Reporting Person's continued service through each vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity does the President, Oncology of CORT report owning?
Roberto Wandenkolk Vieira reports direct ownership of 4,068 shares of Common Stock in CORCEPT THERAPEUTICS INC, including shares underlying several unvested restricted stock awards that vest on their respective one-year anniversaries if service conditions are met.
How many CORT stock options does Roberto Wandenkolk Vieira hold?
He holds options linked to an aggregate of 480,000 shares of Common Stock: 200,000 shares at $21.63, 140,000 shares at $60.58, and 140,000 shares at $35.70, all held directly.
What are the vesting terms of Vieira’s earlier CORT option grant at $21.63?
The option originally covered 400,000 shares, of which 200,000 shares have been exercised. It vested 25% on January 29, 2025, with the remainder vesting monthly over 36 months until fully vested on January 29, 2028, subject to continued service.
When do Roberto Wandenkolk Vieira’s CORT stock options expire?
The option for 200,000 shares at $21.63 expires on February 1, 2034. The option for 140,000 shares at $60.58 expires on February 28, 2035, and the option for 140,000 shares at $35.70 expires on February 27, 2036.
What are the vesting schedules for Roberto Wandenkolk Vieira’s newer CORT option grants?
One option becomes exercisable in equal monthly installments starting from February 28, 2025 over four years. Another becomes exercisable in equal monthly installments starting from February 27, 2026 over four years, in each case subject to his continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
